EICHORCondition: Cardiotoxicity · Sponsor: Beneficência Portuguesa de São Paulo
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Instituto do Câncer do Ceará | Fortaleza, Ceará, Brazil | Not Yet Recruiting |
| Complexo Hospitar HUOC/PROCAPE | Recife, Pernambuco, Brazil | Not Yet Recruiting |
| Universidade Federal de Santa Catarina | Florianópolis, Santa Catarina, Brazil | Not Yet Recruiting |
| Hospital Beneficente UNIMAR | Marília, São Paulo, Brazil | Not Yet Recruiting |
| FAMERP - Faculdade de Medicina de São José do Rio Preto | São José do Rio Preto, São Paulo, Brazil | Not Yet Recruiting |
| Hospital BP - A Beneficência Portuguesa de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07663357